Here, we found that IL20RB overexpression enhanced the resistance of pancreatic cancer cells to gemcitabine, whereas IL20RB knockdown had the opposite effect (Fig. 2I–J). The gene discussed is IL20RB; the disease is familial pancreatic carcinoma.